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ABSTRACT
Brain metastasis is a devastating problem in patients with breast, lung and melanoma 
tumors. GRP94 and FN14 are predictive biomarkers over-expressed in primary breast 
carcinomas that metastasized in brain. To further validate these brain metastasis biomarkers, 
we performed a multicenter study including 318 patients with breast carcinomas. Among 
these patients, there were 138 patients with metastasis, of whom 84 had brain metastasis. 
The likelihood of developing brain metastasis increased by 5.24-fold (95%CI 2.83–9.71) and 
2.55- (95%CI 1.52–4.3) in the presence of FN14 and GRP94, respectively. Moreover, FN14 
was more sensitive than ErbB2 (38.27 vs. 24.68) with similar specificity (89.43 vs. 89.55) 
to predict brain metastasis and had identical prognostic value than triple negative patients 
(p < 0.0001). Furthermore, we used GRP94 and FN14 pathways and GUILD, a network-
based disease-gene prioritization program, to pinpoint the genes likely to be therapeutic 
targets, which resulted in FN14 as the main modulator and thalidomide as the best scored 
drug. The treatment of mice with brain metastasis improves survival decreasing reactive 
astrocytes and angiogenesis, and down-regulate FN14 and its ligand TWEAK. In conclusion 
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our results indicate that FN14 and GRP94 are prediction/prognosis markers which open up 
new possibilities for preventing/treating brain metastasis.
INTRODUCTION
Brain metastasis (BrM) occurs mainly after the 
diagnosis of systemic metastases in up to 30% of cancer 
patients [1, 2]. Despite the improvement in systemic 
therapies and the availability of more frequent imaging, 
central nervous system (CNS) relapse is emerging as an 
increasing clinical problem in up to 40% of cancer patients 
[3, 4]. The mean survival of these patients is 7 months 
[5, 6], posing CNS relapse a key research challenge.
The cross-subtype comparison involving both wet-lab 
and clinical studies reflects the heterogeneity of carcinomas 
to brain metastasis progression [7]. It is now recognized that 
breast cancer is composed of several subtypes [8–10]. The 
large numbers of differentially expressed genes in the five 
molecular subtypes of breast carcinoma confirm the diversity 
of the underlying biology [11]. These biomarkers include 
the estrogen receptor (ER), progesterone receptor (PR), 
and human epidermal growth factor receptor 2 (ErbB2 or 
HER2). ER and PR positivity define Luminal tumors A and 
B, whereas ErbB2 expression occurs in hormone positive and 
in negative tumors and basal tumors are characterized by the 
absence of these biomarkers. Moreover, the clear differences 
in metastatic potential between subtypes raise the question 
as to whether some tumors are “hardwired” to metastasize 
to the brain [12, 13]. Known predictive factors for BrM are: 
(i) overexpression of ErbB2, (ii) lack of hormone receptor 
expression, (iii) triple-negative subtype (TNBC) with ER 
and PR-negative and normal ErbB2, (iv) patient age under 
50 years and (v) the presence of positive regional lymph 
nodes and lung metastases [14, 15]. The basal subtype has 
the worst prognosis (3–4 months) and ErbB2-negative/
hormone receptor positive disease has the best prognosis 
(over 20 months). In a retrospective series of metastatic breast 
carcinoma (MBC) patients treated with trastuzumab, 52% of 
them succumbed to CNS progression although the non-CNS 
disease was stable or responsive [16].
Different primary tumor types exhibit remarkable 
differences in developing BrM. Both small cell and non-small 
cell lung carcinomas, kidney cancer and melanoma are the 
principal tumors with brain metastasis ability [3]. Alterations 
in the expression of several genes, including ST6GALNAC5, 
transforming growth factor-β, vascular endothelial growth 
factor, Serpine 1 and Timp 1 have been implicated in brain 
metastasis [17]. In lung cancer the genes mostly associated 
with brain metastasis are EGFR, KRAS mutation at codon 
12 and several chromosomal imbalances [18].
Therefore, understanding the properties of brain-trophic 
tumor cells is essential to identify patients with risk of brain 
metastasis and to effectively prevent it [19]. A research priority 
is to delineate pathogenic mechanisms of metastasis to the 
brain that would enable the heterogeneity among tumors to 
differentiate between indolent and aggressive lesions.
Patients with ErbB2-positive or TNBC have an 
increased risk of BrM development [20, 21]. A recent study 
reported that both basal-like and claudin-low breast cancers 
exhibited a high probability of metastasizing to the brain and 
lung, while ErbB2-enriched tumors preferentially colonized 
the liver [12]. It has been observed that active WNT/b-catenin 
signaling contributes to the metastasis of basal breast tumors to 
the brain, whereas the absence of WNT/beta-catenin signaling 
allows luminal B-type tumors to metastasize to bone [13]. 
Moreover, a 13-gene signature predicting rapid development 
of brain metastases in patients with ErbB2-positive advanced 
breast cancer may be useful in the design of preventive 
therapies [19]. We identifiedan expression signature based 
on breast cancer BrM cells mapped onto an experimental 
protein–protein interaction network, which found 37 proteins 
differentially expressed in brain metastases [23]. The 
combination of GRP94, FN14 and TRAF2 expression, and 
the absence of Inhibin in breast carcinomas, referred to as the 
endoplasmic reticulum stress resistance phenotype (ERSRP), 
was the best signature for discriminating between breast 
carcinomas according to their BrM progression, regardless of 
whether or not they expressed ErbB-2 [24].
Bearing in mind that metastasis could already be 
underway at the time of diagnosis [25], ERSRP provides a 
predictive tool to help decide on treatment under the risk of 
BrM progression. We performed a multicenter study with 
breast carcinomas provided from three different hospitals 
and assessed ERSRP expression in tissue microarrays to 
independently validate it. Over-expression of GRP94 and 
FN14 in primary breast cancer was confirmed as a BrM 
predictor and the presence of FN14 and GRP94 in pairs 
of tumor/brain metastasis of lung and clear cell kidney 
carcinomas suggest that this phenotype might indicate 
BrM in tumors from different tissues. Moreover, we used 
bioinformatics tools such as BIANA [26] and GUILD [27] 
to prioritize genes implicated in BCBrM progression, and 
based on the network topology we assessed the level of 
association of genes with BCBrM (GUILD scores). We 
then ranked drugs using the GUILD score of their targets 
and produced a list of candidate drugs with high therapeutic 
potential, which were validated in preclinical experiments. 
Moreover, the preliminary experimental results suggested 
that the therapeutic activity of thalidomide derivatives might 
be dependent on brain organspecific microenvironmental 
factors produced by reactive astrocytes.
RESULTS
GRP94 and FN14 are biomarkers that predict brain 
metastasis progression in breast cancer patients
On the basis of retrospective observations, risk factors 
for the development of CNS metastases from breast cancer 
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included patient characteristics and biological features of 
tumors such as ER negativity, ErbB2 positivity, a large 
primary tumor and loss of histopathological differentiation 
[35]. Among clinical parameters the presence of lymph-
node metastasis is intrinsic to establishing the breast cancer 
prognosis [36]. We took all of these parameters into account 
when evaluating the contribution of the previously defined 
breast cancer brain metastasis biomarkers (BCBrMBK): 
GRP94, TRAF2, FN14 and Inhibin [24].
The overexpression of BCBrMBK was categorized as 
positive when strong expression was detected in more than 
70% of tumor cells (Figure 1A). On this basis, GRP94 was 
overexpressed in 48.2% (151/313), FN14 in 17.9% (55/308) 
and TRAF2 in 31.4% (97/309) of tumors. Inhibin expression, 
which was inversely associated with brain metastasis 
progression, was found in only 3.57% (11/308) of samples. 
The variation in the denominators is the result of taking into 
account the missing values in the immunohistochemistry 
data (tissue lost, unviable staining, background, etc.).
We first analyzed the association between the 
overexpression of proteins and the clinico-pathological 
features of the patients (Table 1). Patients with infiltrated 
axillary lymph nodes overexpressed GRP94 (Chi-square 
test, p = 0.049), whereas tumors with a high histological 
grade (III) were associated with FN14 expression (Chi-
square test p = 0.004). The expression of both markers was 
associated with ErbB2 positivity (p = 0.013 and p = 0.005, 
respectively). Moreover, the expression of biomarkers was 
not associated with hormone receptors. The combination 
of negative hormone receptors and ErbB2 expression in 
TNBC patients was independent from the expression of 
GRP94 (p = 0.481) and FN14 (p = 0.914).
Statistical analysis of the data showed significant 
associations between BrM progression and high 
expression of GRP94 (p = 0.0004) and FN14 (p < 0.0001). 
The expression of TRAF2 was marginally associated with 
brain metastasis (p = 0.084). Inhibin was not correlated 
with BrM relapse (p= 0.428).
As expected, the ErbB2 expression detected in 
14.4% (42/292) of patients (26 missing values) was 
significantly associated with BrM (p = 0.003): 24.7% 
(19/77) of breast cancers that progressed to brain metastasis 
were positive versus 12.8% (6/47) and 10.1% (17/168) of 
breast carcinomas that relapsed in other locations (such as 
lung, liver, bone or non-regional lymph nodes) or without 
metastasis, respectively. The incidence of BrM in patients 
with hormone receptors that expressed ErbB2 was 11.5%.
A total of 15.5% (46/297) of patients (21 missing 
values) were triple-negative (TNBC) with an increased 
risk of BrM progression (p < 0.0001). The incidence of 
BrM in this group was 58.7% (27/46); 15.2% (7/46) of 
patients had non-brain metastasis (lung, liver, bone or non-
regional lymph nodes) and 26.1% (12/46) of patients did 
not progress to metastasis (p < 0.0001).
We found no correlation between lung, bone or liver 
metastasis and high levels of expression of BCBrMBK.
The overexpression of GRP94 in patients who 
developed brain metastasis was 65.1% (54/83), whereas 
GRP94 overexpression was found in 42.2% (97/230) 
in the other and non-metastasis group. FN14 was 
overexpressed in 38.3% (31/81) of brain metastasis relapse 
patients and only in 10.6% (24/227) of the others and 
non-metastasis group. The variation in the denominators 
is the result of taking into account the missing values of 
clinicopathological data.
The multivariate analysis comparing samples from 
patients who relapsed in the brain versus those who 
relapsed in other organs and without metastasis, indicated 
that the likelihood of relapse in patients with GRP94-
positive tumors was 2.55-fold higher (95% CI 1.52–4.3, 
p = 0.0003) and increased to up to 5.24-fold higher 
(95% CI 2.83–9.71, p < 0.0001) if the tumors expressed 
FN14 (Table II). The combination of both markers was 
significantly associated to brain metastasis (p = 0.0014). 
These results indicated the predictive potential of both 
molecules for establishing the risk associated with a 
tumor that shows these characteristics. The overexpression 
of TRAF2 in tumors was associated with a 1.60-fold 
increased likelihood of relapse in the brain, although this 
increase was not significant (p = 0.086).
When multivariate analysis was corrected by the 
covariables tumor size, histological grade, lymph nodes, 
hormone receptors, ErbB2, therapy (adjuvant chemotherapy 
and hormones), the best predictive markers for the presence 
of BrM were FN14 (p < 0.0001) followed by GRP94 
(p = 0.0017). These results confirmed the independence of 
both biomarkers from the classical categorization of breast 
carcinomas and from the five breast cancer subtypes, and 
reinforce their intrinsic value as biomarkers for predicting 
BrM relapse, whereas TRAF2 and Inhibin were no longer 
significant (p = 0.481 and p = 0.736, respectively).
A multivariate analysis based on stepwise logistic 
regression retained GRP94 and FN14 as the best 
combination for predicting brain metastasis (Figure 1B). 
We calculated the positive and negative likelihood ratios to 
assess the predictive accuracy of each molecule as a BrM 
marker, considering the sensitivity and specificity of each. 
GRP94 was the most sensitive (0.65) and FN14 the most 
specific (0.89), and the combination of both increased the 
predictability of brain metastasis risk (AUC = 0.69) above 
that ascribed to ErbB2 overexpression (AUC = 0.57). 
Since FN14 had better sensitivity than ErbB2 (38.27% 
vs. 24.68%), the additional information on ErbB2 status 
did not improve the prediction of BrM in breast cancer 
patients (AUC = 0.69). Therefore, the expression of FN14 
in primary tumors was by far the strongest predictor of 
the likelihood of BrM in breast cancer patients and could 
be used to stratify patients according to their risk of 
developing BrM, both for therapeutic decision making at 
first diagnosis and to indicate preventive treatments.
GRP94 and FN14 were also expressed in tumor 
metastasis brain pairs from non-small cell lung carcinoma 
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and clear cell kidney carcinoma patients (Figure 1C). 
Both, FN14 and GRP94 expression in primary tumors and 
the corresponding brain metastasis, being GRP94 more 
sensitive to distinguish brain metastasis ability. In lung 
tumors FN14 expression might be only circumscribed to a 
subtype from those which develop brain metastasis.
The expression of FN14 is a prognostic marker 
in breast cancer patients
The unpredictable clinical behavior of TNBC 
and ErbB2-positive tumors reflects the biological 
heterogeneity of the disease [19, 33, 37, 38]. We analyzed 
BrM-free survival (Figure 2A), the number of months 
from diagnosis of primary tumor to diagnosis of brain 
metastasis, and we correlated with patients according to 
whether the tumors were TNBC (bottom-right panel) or 
expressed ErbB2 (bottom-left panel), FN14 (upper-left 
panel) or GRP94 (upper-right panel). Patients with FN14-
positive tumors (81/308, 10 deleted due to missingness), 
Figure 2A, had a shorter BrM-free survival than patients 
with negative tumors (p < 0.0001) and 31 developed brain 
metastasis; similar to that of TNBC patients (77/301, p < 
0.0001). Patients with ErbB2-positive tumors (77/297, p = 
0.002) and GRP94-positive tumors (83/313, p = 0.002) 
also had a significantly shorter BrM-free survival than 
patients whose tumors did not expressed the protein. These 
results confirmed that FN14 and GRP94 have prognostic 
value as widely accepted breast cancer prognostic markers.
Since adjuvant therapy is selected according to the 
biological features of the primary tumor, and as long-term 
efficacy implies the lack of disease relapse, we assessed 
whether FN14 and GRP94 predicted the response to 
adjuvant therapy by evaluating overall survival (Figure 
2B). Interestingly, patients treated with taxanes survived 
a shorter period with regard to other therapeutic regimens 
(upper-left panel) when tumors expressed FN14 (16/37, 
p = 0.048). In contrast, the survival of patients with FN14-
negative tumors (upper-right panel) was similar in those 
treated with taxanes or with other therapeutic regimens 
(36/150, p = 0.360). These results show that FN14 
predicted taxane protocol failure in breast cancer patients, 
suggesting a relationship between FN14 expression and 
the shortening of BrM-free survival (p = 0.066) in patients 
treated with taxanes (bottom-left panel). In contrast, BrM-
free survival was not associated with the therapeutic 
protocol in patients with FN14-negative tumors (bottom-
right panel).
The association between FN14 expression and 
the efficacy of taxanes against breast cancer in vivo was 
Figure 1: GRP94 and FN14 expression predict brain metastasis progression in breast cancer patients. A. TMAs were 
used to identify the indicated proteins by IHC analysis in paraffin-embedded primary breast carcinomas (x 20). To score the positivity of the 
three proteins we considered samples with more than 70% of tumor positive cells with high levels of staining to represent positive control 
samples (small squares in the left column), ignoring samples with less intense staining or fewer positive cells. (Continued )
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Figure 1: (Continued ) GRP94 and FN14 expression predict brain metastasis progression in breast cancer patients.  
B. The area under the ROC curve obtained with the integrated predictive indexes. Markers were assessed in a multivariate logistic regression 
model using a forward stepwise procedure to identify the best combination for predicting brain metastasis. The area under the ROC curve 
obtained for ErbB2 alone (AUC = 0.57), for GRP94 (AUC = 0.61), FN14 (AUC = 0.64) and the combination of GRP94 and FN14 (AUC 
= 0.69) and for ErbB2, GRP94 and FN14 (AUC = 0.69), is represented in the upper part of the figure. The sensitivity and specificity of the 
markers are shown in the lower part of the figure, indicating the most specific GRP94 and the most sensitive FN14, which was similar to 
ErbB2 in terms of sensitivity and specificity. (Continued )
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explored by performing experiments with two TNBC 
breast cancer xenografts obtained from breast cancer 
patients that expressed (TNBC-EG) or did not express 
(TNBC-1070) FN14 (Supplementary Figure S1A, right 
panel and left panel, respectively). Although docetaxel 
treatment diminished the growth of tumors with regard 
to controls after 15 days of treatment in both models 
(Supplementary Figure S1B), the rate of increase of the 
tumor volume was reduced only 50% (p = 0.003) in FN14-
positive tumors, whereas the rate of increase was reduced 
by 85% (p < 0.001) in FN14–negative tumors with regard 
to the control.
The survival of patients given adjuvant treatments, 
either taxanes or other chemotherapeutic protocols 
(Supplementary Figure S2), was not correlated with 
GRP94 expression in tumors, whether positive (N = 98) or 
negative (N = 92), p = 0.31 and p = 0.29, respectively. These 
results indicate GRP94 and FN14 are involved in different 
pathways and functions in BrM progression, suggesting that 
both biomarkers might be therapeutically inhibited.
Modeling personalized therapies to prevent brain 
metastases using GRP94 and FN14 pathways
The remarkable diversity in breast cancer dictates that 
adjuvant management must be biologically driven [39], and 
thus early breast cancer assessment with tools for prognosis 
and prediction of treatment benefit may aid clinical decision 
making. Indeed, an important question is how to identify 
the specific adjuvant interventions that would improve the 
prognosis of BC patients with risk of BrM progression. Since 
the pathophenotype is the outcome of perturbations in the 
underlying regulatory pathways, we designed experiments 
to highlight the usefulness of BCBrMBK expression in 
choosing the most appropriate adjuvant therapy.
We have previously cataloged the organ-specific 
metastasis signature (BOSMS) with a hierarchical 
clustering containing 1,193 genes after one-versus-all 
(ONA) class comparisons, which clearly distinguished 
between the different metastases [40]. These datasets, 
under the identification number GSE11078, are freely 
available from the Gene Expression Omnibus (GEO) 
repository. The BOSMS mapped human brain metastasis 
expression profiles with a PPIN to maximize accuracy 
in the classification of brain metastasis proteins and 
permitted the identification of protein folding and 
chaperones connecting different functions and performing 
the endoplasmic reticulum stress resistance phenotype 
(ERSRP) [24]. Indeed, rather than having random 
connections through the network, the interaction of 
proteins encoded by genes implicated in such phenotypes 
involves partners from similar diseases [26]. We used these 
Figure 1: (Continued ) GRP94 and FN14 expression predict brain metastasis progression in breast cancer 
patients. C. Expression of GRP94 and FN14 in four pairs tumor/BrM of lung and clear cell kidney carcinomas. Representative IHC of 
BrM are showed in the upper part of the figure and at the bottom the relation of positive samples of each protein.
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data, together with systems biology and computational 
approaches, to create treatment strategies using the 
BCBrMBK. First we listed the brain organ-specific 
genes/proteins [24, 41], including up- and downstream 
molecules of signaling pathways connected functionally 
with GRP94 and FN14 (Supplementary Table S1). Using 
GUILD, a bioinformatics software [28], the brain organ-
specific genes and the PPIN, we prioritized the genes 
for BCBrMK based on the network topology. The best-
positioned molecule in the ranking was FN14, followed 
Table 1: Association between clinical and pathological characteristics and the expression of 
breast cancer brain metastasis biomarkers
GRP94 FN14 TRAF2
(N = 313)* (N = 308)* (N = 309)*
No. Patients (%)** No. Patients (%)** No. Patients (%)**
151 (48.2) 55 (17.9) 97 (31.4)
Tumor Size
≤ 2 cm 78 (45.6) 24 (14.2) 55 (32.7)
> 2 cm 65 (52.8) 25 (20.7) 34 (27.7)
Chisq2 test p = 0.269 Chisq2 test p = 0.198 Chisq2 test p = 0.422
Axillary Lymph Node
0 78 (50.7) 23 (15.0) 44 (28.8)
1–3 30 (37.0) 13 (16.5) 25 (31.7)
≥4 37 (56.1) 15 (23.4) 22 (33.9)
Chisq2 test p = 0.049 Chisq2 test p = 0.320 Chisq2 test p = 0.738
Histological Grade
I 5 (31.3) 3 (18.8) 6 (37.5)
II 74 (51.8) 14 (9.8) 43 (30.5)
III 66 (50.0) 32 (25.2) 41 (31.5)
Chisq2 test p = 0.298 Chisq2 test p = 0.004 Chisq2 test p = 0.848
Steroid Receptors
  Estrogen + 104 (46.9) 34 (15.5) 70 (31.8)
  Estrogen − 37 (48.7) 18 (24.3) 23 (31.1)
Chisq2 test p = 0.886 Chisq2 test p = 0.124 Chisq2 test p = 0.979
  Progesterone + 87 (45.1) 33 (17.3) 57 (29.8)
  Progesterone − 52 (51.5) 19 (19.4) 35 (35.4)
Chisq2 test p = 0.356 Chisq2 test p = 0.779 Chisq2 test p = 0.411
ErbB2
  Positive 27 (65.9) 14 (35.0) 17 (42.5)
  Negative 110 (43.7) 38 (15.1) 75 (29.9)
Chisq2 test p = 0.013 Chisq2 test p = 0.005 Chisq2 test p = 0.158
Subtypes
  Triple Negative 18 (41.9) 7 (16.2) 12 (27.9)
  Others 125 (49.0) 46 (18.3) 82 (32.5)
Chisq2 test p = 0.481 Chisq2 test p = 0.914 Chisq2 test p = 0.671
*The variation in the denominators is the result of taking into account the missing values in the IHC data (tissue lost, 
unviable staining, background, etc.).
**The percentages of positive tumors distributed according to clinical and pathological characteristics of patients.
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by TRAF2, TANK, TP53 and HSP90B1 (GRP94) in fifth 
position (Supplementary Table S2).
Candidate drugs in brain metastatic breast cancer 
were retrieved from the DrugBank and drugs were ranked 
using the score for brain metastasis proteins (Figure 3). As 
shown at the bottom of Figure 3, the most specific drugs 
intercepting the BCBrMBK pathways are thalidomide, 
overall score (o.s.) = 0.195, vorinostat o.s. = 0.095 and 
bevacizumab o.s.= 0.078.
The ranking of molecules under thalidomide 
therapeutic action included TNFα as the best therapeutic 
target in position 194. Other proteins linked to thalidomide 
therapy were positioned downstream: PTGS2 (246), NFKB1 
(1326), and FGFR2 (5800), (Supplementary Table S3).
Other drugs retrieved from the DrugBank for the 
drugs in the Medtrack file were: cytarabine, lomustine 
and methotrexate, which mechanism of action involved 
POLB, STMN4 and DHFR, respectively (Supplementary 
Table S3). Temozolamide was retrieved without a known 
molecule. Heat shock inhibitors were retrieved from the 
DrugBank below position 8659, the rank of bevacizumab 
action over the VEGFA protein.
Targeting FN14 with thalidomide derivatives 
improves brain metastasis outcome in preclinical 
experimental models
Since GUILD retrieved FN14 as the main 
regulator of BrM protein-protein interacting network, we 
hypothesized that thalidomide therapy could impair FN14/
TWEAK function in the BrM.
It is well known that FN14 belongs to the TNFR 
family and is activated by its specific ligand TWEAK 
and by TNFα [42]. Among other cytokines TWEAK 
is expressed in brain, mainly produced by astrocytes 
and microglial cells [43]. The binding of TWEAK to 
FN14 has a direct effect on the composition of the basal 
lamina (BL) and on the perivascular astrocytes (PA), 
regulating their interaction with endothelial cells (EC) 
and regulating the function of the BBB in the EC-BM-
astrocyte interface [44].
To analyze if LND can impair FN14/TWEAK 
in vivo, we performed experiments to inhibit BrM growth 
in a classical model of brain metastasis [30], where the 
proprietary cells BRV5eGFP-CMV/Luc (BrV5), obtained 
from 435Br1 cells by in vivo/in vitro selection, were 
injected intra-cranially by stereotaxia to homogenize the 
groups of treatment. The cellular burden was followed by 
luminescence to assess the volume slope of intracranial 
masses in animals treated with the vehicle or with a 
thalidomide derivative lenalidomide (LND), the weight of 
the animals was monitored three times a week (m-w-f) and 
the bioluminescence analysis was done twice a week (m-f) 
until the symptoms of metastasis appeared. The differences 
observed in the increasing rate of bioluminescence 
between the two groups (treated or not with LND) were 
not statistically significant (Student test, p = 0,39), due 
in part to the heterogenic growth of cells (Figure 4A). 
In addition, we analyzed mice survival and the results 
showed moderate differences (Figure 4B) between treated 
and non-treated mice (p = 0.080). The IHC analysis of 
brain tissues showed that LND decreased the expression 
of FN14 in tumoral cells (Figure 4C).
These results fit with the survival of 435Br1 cells 
stimulated with TWEAK (Supplementary Figure S3A 
and S3B), which increased with regard to parental cells, 
suggesting the high functionality of the FN14/TWEAK 
pathway. Moreover, we found an IC50 > 100 μM when 
challenged 435Br1 cells with LND. Therefore, LND 
does not exert in vitro cytotoxicity against carcinoma 
cells, as was the case in human myeloma cell lines 
challenged in vitro with the cell-extrinsic component of 
the antineoplastic activity of LND, which prevails over 
its cell-intrinsic counterpart [45]. In contrast, 435Br1 
cells overexpressed GRP94 (Supplementary Figure S4A), 
and the heat shock protein inhibitor (NVP-AUY922) 
[46] was highly cytotoxic and the IC50 was 10–20 nM 
(Supplementary Figure S4B).
Table 2: Odds ratio for brain metastasis according to the expression of breast cancer brain 
metastasis biomarkers in primary tumors
Metastases Incidence
BRAIN OTHERS & NON 
MET
OR (95% CI) p - value 
GRP94 54/83(65.1%)
97/230
(42.2%) 2.55 (1.52 - 4.3) 0.0003
FN14 31/81(38.3%)
24/227
(10.6%) 5.24 (2.83 - 9.71) < 0.0001
TRAF2
32/82
(39.0%)
65/227
(28.6%) 1.60 (0.94 - 2.71) 0.0859
* The variation in the denominators is the result of taking into account the missing values in the IHC data (tissue lost, 
unviable staining, background, etc.).
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Figure 2: Kaplan-Meier survival estimates of brain metastasis-free survival among patients. A. According to the 
expression of FN14 (total N = 308, events N = 81), GRP94 (total N = 313, events N = 83), ErbB2 (total N = 297, events N = 77) and TNBC 
(total N = 301, events N = 77). The p values were obtained from the log-rank test. B. Kaplan-Meier survival estimates of overall free 
survival (both upper panels) and brain metastasis-free survival (both bottom panels) among patients who received chemoadjuvant therapy, 
with or without taxanes, according to the FN14 expression in tumors.
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We analyzed the contribution of the CNS micro-
environment in brain metastasis from treated and 
control mice. The expression of reactive astrocytes 
around cancer cells diminished together with the 
down regulation of TWEAK and CD31 expression in 
treated mice with regard to controls (Figure 4D). These 
results indicated that LND had a microenvironmental 
action in BrM that can involve astrocyte response and 
angiogenesis.
Furthermore, we analyze LND activity in adjuvancy 
with the cytotoxic drug, synchronizing the same scheme of 
LND treatment with NVP-AUY922 (Figure 4E and 4F). 
The mice had a significantly lower tumor burden slope than 
those treated with the vehicle or with NVP-AUY922 alone 
and the survival of mice differed significantly between 
groups (NVP-AUY922 + LND vs. CTR, p= 0.012; NVP-
AUY922 + LND vs. NVP-AUY922, p = 0.033). In contrast, 
the survival of mice treated with NVP-AUY922 alone 
Figure 3: Modeling personalized therapies to prevent brain metastases using GRP94 and FN14 pathways as 
targets. Workflow chart describing the process of prioritizing genes involved in breast cancer brain metastasis based on network topology, 
retrieval of drugs from the DrugBank and ranking of these drugs using the GUILD score to determine the best treatment. The list of targets 
prioritized is shown at the bottom, indicating that thalidomide is the best drug to target FN14.
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Figure 4: Experimental brain metastasis models to validate the therapeutic effect of a thalidomide derivative. Lenalidomide, 
50 mg/Kg/day, alone or in combination with Docetaxel 15 mg/Kg/day and NVP-AUY922 (NVP) 30 mg/Kg/day. Docetaxel was administered 
every 4 days for 2 weeks and NVP-AUY922 every 2 days for 2 weeks. A. Representative images show bioluminescence in animals at day 5, 12 and 
22 from the start of LND treatment 50 mg/Kg/day every day (Celgene Corporation, Summit, NJ). B. The survival time (box plot) of mice treated 
with LND (N = 8) or with vehicle (Control, N = 8) was evaluated using the log-rank test (p = 0.0802) and the differences observed in the survival 
rate between the two groups (treated or not with LND) are represented. C. IHC analysis in paraffin-embedded experimental brain metastasis 
(x 20) shows the downregulation of FN14 in mice treated with LND. D. IHC analysis in paraffin-embedded experimental brain metastasis (x 20). 
Representative figures showing the upfront of the metastasis invading the brain tissue in controls (upper part of the figure). Each protein expressed 
is indicated. CD31 a. GFAP b. and TWEAK  c. Decreased angiogenesis  d. few reactive astrocytes  e. and downregulation of TWEAK  f. indicated 
with arrows in tissues from mice treated with LND with regard to controls (lower part of the figure). (Continued)
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Figure 4: (Continued ) Experimental brain metastasis models to validate the therapeutic effect of a thalidomide 
derivative. E. Representative images show bioluminescence in animals at day 22 from the start of indicated treatments. The 
bioluminescence data were transformed using the log(1+x) function (where x = AvR), in order to obtain a more regular and positive 
distribution. Subsequently, these data were normalized by subtracting the first observation (day 14) from each of the following observations. 
F. The survival time (box plot) of mice treated with NVP-AUY922 (N = 6) alone or in combination with LND (N = 6) are shown. The 
differences in mouse survival were statistically significant in NVP-AUY922 + LND vs. CTR (p = 0.012) and NVP-AUY922 alone vs 
NVP-AUY922 + LND (p = 0.033); but the survival of mice treated only with NVP-AUY922 and controls was similar (p = 0.351).  
G. IHC of brain metastasis from mice treated with NVP-AUY922 alone and in convination with LND. The expression of GFAP indicative 
of reactive astrocytes is higher in NVP-AUY922 + LDN group than in brain metastasis from mice treated with NVP-AUY922 alone.  
H. Athymic Nude-Foxn1nu female mice. The xenograft expression of GRP94 and FN14 is shown in the upper part, in tumoral cells 
(GRP94) and in tumor and estromal cells (FN14). The statistical differences between groups of treatment (*): control treated with vehicle 
(N=17), Docetaxel (N=10),  LND (N=16), NVP (N=15), NVP+LND (N=9) and Docetaxel+LND (N=20) according the volume slope are 
indicated at the bottom of the figure.
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and control mice was similar (NVP-AUY922 vs. CTR, 
p = 0.351). Reactive astrocytes decreased according to the 
expression of GFAP in NVP-AUY922 + LND with regard 
to NVP alone (Figure 4G). These results suggested that the 
therapeutic effect of LND might contribute to the success of 
adjuvant treatment by decreasing reactive astrocytes and/or 
modifying the BBB penetration [44].
In addition, to avoid BBB permeability maintaining 
the stromal and phenotypic characteristic of brain 
metastasis tissue, we treated a group of mice with a 
subcutaneously engrafted brain metastasis biopsy, which 
expressed both GRP94 and FN14 proteins, obtained 
from a woman with primary lung carcinoma that 
metastasized in the brain. We compared tumor growth 
in mice treated with LND, docetaxel and NVP-AUY922 
alone or in combination with LND (Figure 4H). LND 
alone (p = 0.046) reduced the engrafted brain metastasis 
in mice, even more in combination with docetaxel (p = 
0.004), in contrast to docetaxel alone (p = 0.179). These 
preliminary results showed that LND might improve 
therapy responses in brain metastatic tissue. Moreover, 
NVP-AUY922 decreased graft development alone (p = 
0.006) and in combination with LND (p = 0.004). In this 
case the high cytotoxicity of the drug is manifested when 
BBB is avoided.
These preliminary results suggested that the action 
of thalidomide derivatives could impair FN14/TWEAK 
axis through its reactive astrocytes activity. In fact, 
LND did not reduce the tumor slope of i.m.f.p. breast 
cancer tumors induced with EG and 1070 TNBC breast 
carcinomas (Supplementary Figure S5), even thought 
decreased the expression of FN14 positive EG tumors, 
probably intercepting other stromal cytokines production.
DISCUSSION
To our knowledge, this study is the first to report 
that fibroblast growth factor-inducible protein 14 (FN14) 
expression and GRP94 expression in a patient diagnosed 
with breast cancer (BC) indicates a high risk of brain 
metastasis (BrM) progression, offering the opportunity to 
develop therapeutic strategies either to prevent the disease 
or facilitate early detection. Moreover, other tumors like 
lung carcinomas and clear cell kidney carcinomas might 
express these biomarkers according their ability to develop 
BrM.
The major challenge for both primary and 
secondary prevention studies is the identification of 
patients at highest risk of developing brain metastasis 
due to tumor and host factors. For cancers of the breast, 
BrM occurs after diagnosis of systemic metastases from 
tumors belonging to one of two categories: tumors with 
amplification of ErbB2 or TNBC; the incidence of both 
exceeds one-third of patients [47, 48]. We demonstrate 
that FN14 and GRP94 are independent prognostic factors 
and give information on the likelihood that patients 
will develop brain metastasis, either in ErbB2 or TNBC 
patients.
FN14 positivity was associated with ErbB2 
expression in our series, consistent with reports 
that high FN14 expression levels were significantly 
correlated with several poor prognostic indicators, being 
higher particularly in ErbB2-positive breast cancer 
[49]. Moreover, FN14 positive tumors might have a 
poor survival because they are likely to develop brain 
metastasis. On the other hand, GRP94 correlates with 
ErbB2 expression and poor BrM free survival of breast 
cancer patients. Indeed, GRP94 specific inhibitors 
provided evidence for the role of GRP94 in maintaining 
the architecture of high-density ErbB2 formations at 
the plasma membrane, which is vital for proper ErbB2 
functioning [50].
FN14 is a small cell-surface protein that might 
modulate cell–extracellular matrix interactions, the 
expression of which is frequently found to be strongly 
enhanced in tumor tissue compared to non-transformed 
tissue [49]. The tumor microenvironment typically 
contains many factors implicated in the upregulation of 
FN14 expression [51]. High FN14 has been found in 
tissues damaged by different insults including hypoxia, 
oxidative stress, chemical and mechanical injuries and 
tumor growth [52]. Although the regulatory elements 
involved in FN14 gene activation have not yet been 
elucidated, the human FN14 promoter region contains 
several potential transcription factor binding sites, 
including AP-1 sites and the NFkB site [53]. RNA 
interference-mediated inhibition of FN14 expression in 
metastatic MDA-MB-231 breast cancer cells reduces 
invasion through activation of the NF-kB pathway [49]. 
Moreover, FN14 has been shown to promote breast cancer 
cell migration, invasion and MMP9 expression [54]. 
These data illustrate the importance of FN14 expression 
in mechanistic pathways of metastasis progression.
Brain colonization involves many factors implicated 
in the upregulation of FN14 expression. Among them, 
reactive astrocytes [55] represent a bona fide source of 
TWEAK (TNF-like weak inducer of apoptosis), its only 
known signaling-competent receptor [51]. Further work 
is required to unraveling the important role that FN14/
TWEAK axis in different pathogenic steps of brain 
metastasis progression, including BBB permeability.
Consistent with the hypothesis that LND action 
might involve the physical and tropic interaction between 
cancer cells and the CNS environment, the treatment of 
experimental brain metastasis resulted in a reduction in 
tumor volume with reactive astrocytes and angiogenesi 
decrease and down-regulation of FN14 and TWEAK 
expression. A similar therapeutic effect has been reported 
with the use of immunotoxins targeting the FN14 receptor 
[56]. Indeed, a phase I study of RG7212, a humanized 
anti-TWEAK IgG1k monoclonal antibody, was conducted 
in patients with advanced solid tumors expressing FN14 
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resulting in tumor regression and prolonged stable disease 
[57]. This is the first evidence of a specific treatment 
against FN14/TWEAK that encourage the use of these 
molecules as a therapeutic target to develop new drugs to 
treat/prevent brain metastasis.
LND is a synthetic derivative of thalidomide currently 
approved by the US Food and Drug Administration for use 
in patients affected by multiple myeloma (in combination 
with dexamethasone) and low or intermediate-1 risk 
myelodysplastic syndromes that harbor 5q cytogenetic 
abnormalities [58]. Therefore, our results illustrate a new 
indication of LND for the treatment of brain metastasis 
when the primary tumor expresses FN14. Pomalidomide 
(CC4047) is a new thalidomide derivative with high in 
vitro potency. A first phase 1b, single-center, ascending 
dose study was conducted to identify the maximum 
tolerated dose (MTD) and evaluate the safety and efficacy 
of CC-4047 in relapsed or refractory LND-treated MM 
patients (http://ClinicalTrials.gov, number NCT01311687, 
and with EudraCT, number 2010–019820-30), showing 
a significantly longer median overall survival time with 
refractory or relapsed multiple myeloma patients [59].
BrM are remarkably heterogeneous in permeability 
to the chemotherapeutic agents, typically undergo higher 
levels of drug penetration than surrounding normal 
tissue, but far lower levels of penetration than metastases 
to other organs [60], due of drug efflux pumps for 
chemotherapeutic and molecular therapeutic agents [17]. 
Since St Gallen Consensus [61] is indicating cytotoxic 
drugs in TNBC, due to the limit distribution of taxanes 
to subtherapeutic levels in brain, it could be beneficious 
to treat FN14 positive tumors with drugs that have better 
penetration to CNS. This consideration might prevent to 
render the brain a ‘‘sanctuary site’’ for metastatic cells in 
TNBC patients.
On the other hand, in all meta-analyses involving 
taxane-based regimens or anthracycline-based regimens 
[62], the proportional reductions in early recurrence, any 
recurrence, and breast cancer mortality appeared largely 
independent of age, nodal status, tumor diameter, tumor 
differentiation (poorly or moderately differentiated, 
relatively few were well differentiated) or ER status 
(ER-poor or ER-positive). Indeed, for a patient with 
early-stage breast cancer, recommendations regarding 
systemic therapy and the most appropriate choice of 
agent(s) are often difficult (Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG)). In this scenario, FN14 
over-expression is an early event, which reflects specific 
mechanisms of breast cancer progression, correlates with 
clinico-pathological features and predicts BrM outcome 
in patients treated with protocols including taxanes. 
Therefore, FN14 combines prediction and prognostic 
information to stratify patients at first diagnosis according 
to the likelihood of BrM with accuracy similar to ErbB2, 
and thus it might help clinicians in deciding the therapeutic 
protocols to be adopted.
To date only ErbB2-positive breast cancer patients 
have entered prevention trials to clarify the role of 
lapatinib [63]. Most patients with BrM are suffering 
from terminal cancer, and control of brain metastasis 
is crucial for their quality of life. ErbB2-positive BC 
has seen more therapeutic progress than TNBC. The 
LANDSCAPE trial is a phase II study testing lapatinib 
plus capecitabine in previously untreated BCBrM and was 
positive for its primary endpoint, with 65.9% of patients 
presenting a partial response. In the light of these results 
we suggest that patients with triple-negative tumors and 
pulmonary metastasis might be the most suitable group 
for prospective trials investigating strategies for BrM 
screening and prevention. Indeed, FN14 and GRP94 might 
be a companion diagnostic markers that could identify 
patients who are likely to respond to drugs interfering with 
these specific targets.
Progress in treating brain metastases has been 
hampered by a lack of model systems, a lack of human 
tissue samples, and the exclusion of brain metastatic 
patients from many clinical trials. The Response 
Assessment in NeuroOncology (RANO) group has 
recently published the endpoints and trial consideration in 
brain metastases clinical trials [64]. This is clearly but the 
beginning of such considerations.
BrM therapy faces the challenge of efficiently 
targeting cancer cells or/and their supportive relationship 
with the brain parenchyma. Nowadays, the treatment 
armamentarium consists of a multimodality approach, 
selected according to the patient’s symptoms and extent 
of disease. A systemic therapy might even prevent brain 
colonization altogether or at least arrest single cells 
or micrometastases in the dormant state. The role of 
thalidomide derivatives in preventing BrM progression is 
an ongoing investigation in our laboratory, with a particular 
focus on their hypothetical mechanism of action which 
might be associated with the regulation of immunoreactive 
astrocytes in the area surrounding BrM cells.
MATERIALS AND METHODS
Sample collection
We recruited samples from 318 patients diagnosed 
between 1989–2009 in three hospitals: 252 samples from 
the Catalan Institute of Oncology (I.C.O.) – Hospital 
Duran i Reynals and the Hospital Universitari de Bellvitge 
(L’Hospitalet de Llobregat, Spain); 24 samples from the 
Consorci Hospitalari Parc Taulí (Sabadell, Spain) and 
42 samples from I.C.O. – Hospital Universitari Germans 
Trias i Pujol (Badalona, Spain). The patients were between 
24–88 years old at diagnosis and 61% were diagnosed 
when in/older than their fifties (mean: 55 years). Follow-
up ranged from 8 to 146 months (mean: 76.6 months). 
Metastasis relapse occurred in 43.4% (138/318) of 
patients; of these, 84 patients (60.9%) developed BrM, 
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47 (34.1%) lung metastasis, 54 (39.1%) liver metastasis, 
40 (29.0%) non-regional lymph node metastasis and 89 
(64.5%) bone metastasis. Just over half (56.6%; 180/318) 
of the patients had no metastatic progression after a 
minimum follow-up of 5 years.
In terms of histological type, the ductal type was 
identified in 94.1% (n = 299) of patients, followed by 
lobular in 5% (n = 16), mucinous in 0.6% (n = 2) and 
medullary in 0.3% (n = 1). Estrogen receptors (ER) 
were analyzed in 304 patients, being positive in 74.7% 
(n = 227); relevant data were missing in 14 patients. 
Progesterone receptors (PR) were evaluated in 299 
patients (missing in 19), being positive in 65.9% (n = 197). 
ErbB2 scoring was obtained for 296 patients (22 cases 
missing), only 14.2% (n = 42) of whom were positive. 
The triple-negative status was analyzed in 302 patients (16 
cases missing), with only 15.6% of them (n = 47) being 
identified as triple-negative.
Sixty-three percent (193/307) received adjuvant 
chemotherapy: schedules with CMF (n = 68), anthracyclines 
(n = 32), anthracyclines plus CMF (n = 60), taxanes (n = 
21) and anthracyclines plus taxanes (n = 12); 6 patients 
were missing and 5 were not undergone to surgery. Only 3 
patients received trastuzumab as adjuvant therapy. Twenty-
nine percent (91/314) of patients received neoadjuvant 
chemotherapy and adjuvant hormonotherapy was prescribed 
in 65.1% (203/312); 1 case was missing and 5 not undergone 
to surgery. The variation in the denominators is the result 
of taking into account the missing values in the clinical-
pathological parameters.
Tissue microarrays (TMAs) and 
immunohistochemistry (IHC)
TMAs were prepared from three representative 
areas of the tumor that were carefully selected from 
hematoxylin-eosin-stained sections of the donor blocks. 
Core cylinders of 1 mm diameter were punched from 
each tumor using a skin-biopsy punch and deposited into 
recipient paraffin blocks using a specific arraying device 
(Beecher Instruments, Sun Prairie, WI) as described 
elsewhere [24]. Three-μm sections of the resulting tissue 
microarray block were cut and used for IHC analysis after 
being transferred to glass slides.
To optimize each immunohistochemical analysis, 
the corresponding control tissues for the expression of 
each protein were also used. Antigens were retrieved 
by heating in a pressure cooker for 7 minutes in the 
appropriate buffer. Primary antibodies anti-GRP94 at 
1/2000 (sc-1794) and anti-FN14 at 1/3000 (sc-27143), 
both Santa Cruz Biotechnology (Santa Cruz, CA) and anti-
TRAF2 at 1/100 (SM7106P, Acris Antibodies, Herford, 
Germany) were diluted in Dako Real™ Antibody Diluent 
Buffer (Dakocytomation; Dako, Glostrup, Denmark): 
Tris buffer, pH 7.2, 15 mM Na3N. LSAB+System-HRP 
(Dakocytomation) was used, including biotinylated anti-
rabbit, anti-mouse and anti-goat immunoglobulins in PBS; 
streptavidin conjugated to HRP in PBS; and liquid 3–3′ 
diaminobenzidine in chromogen solution. The polyclonal 
antibody anti-ErbB2, A0485 (Dako) was used with the 
Ultraview detection kit in an automatic staining system 
(Benchmark XT, USA).
Staining optimization, evaluation parameters and 
analyses were established by two pathologists who were 
blinded to the clinical status. The overexpression of 
GRP94, FN14 and TRAF2 was categorized as positive 
when strong expression was detected and negative when 
no or weak expression was detected, in order to avoid 
false positives (Figure 1A), taking into account the known 
expression in a control tissue, as previously reported [24].
Four tumor-metastasis pairs of kidney and lung 
carcinoma from paraffin archives were used to explore the 
expression of biomarkers in tumors different from breast.
Prioritization of brain metastasis candidates 
using protein–protein interactions
First, a protein–protein interaction subnetwork 
(PPIN) of the whole human interactome was built 
around a set of proteins known to be crucial for 
brain metastatic growth (i.e., root proteins). All the 
interactions of root proteins were retrieved from 
BIANA, provided that the interaction had been 
identified using an experimental method other than a 
pull-down method. Though suitable for defining protein 
complexes, interactions from pull-down methods might 
introduce spurious binary interactions between proteins. 
Then, gene expression levels were mapped onto the 
network. A protein was considered to be differentially 
expressed if the gene encoding for it was differentially 
expressed in the tissue microarray experiment. This 
mapping allowed us to find the active subnetworks: 
clusters of the network with a significant proportion of 
proteins produced by up- and down-regulated genes. 
Next, we calculated a brain metastasis likelihood score 
for all the nodes in the human interactome using GUILD 
[27], a network-based disease-gene prioritization 
software. GUILD assigns a disease-implication score to 
each node in the network by disseminating information 
about roots (known metastatic growth proteins) to other 
nodes through the links in the network. It can also be 
used to prioritize drugs for their potential to intervene 
in a given disease by considering the scores of the drug 
targets [28]. We used 15 root proteins (selected from 
those identified by proteomics analysis) for which 
we found interactions in the human interactome (see 
Supplementary Table S1). We applied the NetCombo 
algorithm implemented in GUILD, which produces a 
consensus score that considers the distance from the 
nodes to the roots in the network.
Next, we used the GUILD scores assigned 
to proteins to rank candidate drugs (listed in 
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Supplementary Table S4). For each drug, we calculated 
the average GUILD score of its known targets. Drug-
protein information was retrieved from the DrugBank 
database [29].
Animal models
Athymic Nude-Foxn1nu female mice weighing 
22–28 g were purchased from Harlan Laboratories S.A. 
(Barcelona, Spain) and were housed in the IDIBELL 
facility in SFP conditions, at 20–24°C, 60% relative 
humidity, and 12–12-hour light-dark periods. Animals 
were allowed free access to UV-irradiated water and an 
adequate sterile diet. All animal-related procedures were 
performed in accordance with the National Institute of 
Health Guidelines for the Care and Use of Laboratory 
Animals, with the approval of the animal care committee.
Xenografts from primary tumors and brain metastasis 
biopsies
Samples were collected at Hospital Universitari de 
Bellvitge (L’Hospitalet de Llobregat, Barcelona, Spain). 
The study was approved by the Institutional Review 
Board. Written informed consent was collected from 
patients. Non-necrotic tissue pieces (2–3 mm3) from 
resected ductal breast carcinoma (TNBC-EG and TNBC-
1070) or brain metastasis biopsies (BrM1110) were 
placed in DMEM (BioWhittaker) supplemented with 
10% FBS and penicillin/streptomycin. The xenografts 
were implanted in animals under isofluorane-induced 
anesthesia, either in the intramammary fat path (i.m.f.p) 
or subcutaneously when the biopsy belonged to primary 
breast carcinoma or brain metastasis, respectively. When 
the i.m.f.p. tumors reached ~1000 mm3, they were excised, 
dissected into 2–3 mm3 cubes and transplanted into 
additional mice using the same procedure.
Brain metastasis in vivo experiments
To induce brain metastases the highly brain 
metastatic cell line BR-eGFP-CMV/Luc-V5CA (BRV5) 
[30] was intracranially implanted [31]. In brief, 435-Br1 
cells originally established from a brain metastasis in a 
nude mouse orthotopically inoculated with the triple 
negative MDA-MB 435 parental cell line [32], contain the 
retroviral vector preGFP-CMV-PLuc with the enhanced 
green fluorescent protein (eGFP) gene, under the control 
of the 5′ LTR, and the photinus luciferase (PLuc) gene, 
under the control of the cytomegalovirus (CMV) promoter 
[33]. Vector preparation and packaging of viral particles 
was performed as described previously. A cell population 
that uniformly expressed the highest levels of eGFP 
(BR-eGFP-CMV/Luc) was selected by FACS (MoFlo, 
Cytomation, Dako, Denmark). Left ventricle (LV) 
injection of cells and their further isolation from mouse 
brain was repeated five times, obtaining BR-eGFP-CMV/
Luc-V1 to V5 cells through these cycles.
The controversial use of MDA-MB 435 cells has 
been recently clarified, since it has been demonstrate that 
MDA-MB 435 cells are an useful breast cancer model that 
expresses both, epithelial and melanocytic markers [34].
Animals were anesthetized by intraperitoneal 
injection of ketamine/ medetomidine, with a previous 
subcutaneous injection of buprenorphine, and placed 
in a stereotactic apparatus. An incision was made over 
the cranial midline with a scalpel, and a hole 1 mm 
posterior to the bregma and 2 mm to the right of the 
midline was made with a 25 gauge needle by hand. 
Two microliters of the cell suspension at 107 cells/ml 
in HBSS was infused with a Hamilton® 10 μl syringe 
(Bonaduz, Switzerland) and a Hamilton® needle 
(ga26s/51mm/pst2). Finally, the incision was sutured 
and medetomidine was added as the antidote. Animals 
were imaged and weighed three times within a week (on 
Monday, Wednesday and Friday), and were euthanized 
when they showed signs of declining health and visible 
body weight loss.
In vivo bioluminescence imaging
Mice were injected subcutaneously with 10 μl/g 
body weight of D-Luciferin (Biosynth AG) 15 minutes 
before imaging. We anesthetized the animals with 4% 
Isofluorane gas in 2 l/min O2 and maintained anesthesia 
inside the chamber with 2% Isofluorane at 2 l/min O2 during 
acquisition. The animals were placed in the prone position. 
Cells showing bioluminescence were detected and quantified 
using the Living Image 4.1 image analysis software (Caliper, 
LifeSciences Hopkinton, MA). The parameter chosen for 
treatment evaluation was the total flux (p/s).
The background signal of each mouse (photons 
emitted by the mouse before the injection of luciferin) was 
subtracted in every bioluminescence cranial measurement.
The bioluminescence analysis was conducted once 
a week during the early stages of the disease and twice 
a week when brain masses began to grow exponentially.
Histology and immunohistochemical tumor 
characterization in mice
The morphology of the engrafted tumors and brain 
metastases was analyzed by H&E staining in paraffin-
embedded sections. Determination of GRP94, FN14 and 
TRAF2 was performed as described previously. IHC 
analysis with anti-CD31 (Dako) at (1/100), anti-TWEAK 
(Abcam, Cambridge, UK) at (1/300) and anti-GFAP 
(Dako) at (1/16000) were performed.
Therapeutic protocols
For brain metastasis treatment, we started therapy on 
day 14 once the mice had recovered from surgery and after 
checking the success of cell inoculation.
Lenalidomide (LND), a thalidomide derivative, was 
obtained from the Celgene Corporation (Summit, NJ) and 
from Sellek Chemicals LLC (Houston, TX). LND was 
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injected intraperitoneally in DMSO (Sigma-Aldrich) at 
50 mg/Kg/day, every day until the end of the experiment. 
Docetaxel (TXT) and NVP-AUY922 (NVP), both from 
LC Laboratories, were injected intraperitoneally in 
DMSO at a dosage of 15 mg/Kg/day and 30 mg/Kg/day 
respectively. TXT was administered every 4 days for 2 
weeks and NVP every 2 days for 2 weeks.
Statistical analysis
To evaluate the correlation between protein expres-
sion and brain metastasis in patients, immunostained 
samples were graded on a three-category scale (negative, 
weak positive, and strong positive). The marker was 
classed as being overexpressed in strong positive samples. 
The association with brain metastasis for each marker was 
tested using a two-sided Fisher exact test and summarized 
by calculating the sensitivity among tumors that developed 
metastasis, and specificity among tumors without metastasis, 
for strong positive values. Positive and negative likelihood 
ratios were also calculated as integrated predictive indexes, 
as was the area under the ROC curve. Markers were 
assessed using a multivariate logistic regression model in a 
forward stepwise procedure to identify the best combination 
for predicting brain metastasis. Since ErbB2 was already a 
known metastasis risk factor, an analysis including ErbB2 
as the baseline was also performed, as well as a stratified 
analysis of each candidate marker within ErbB2-positive 
and -negative tumors. In all analyses, associations were 
considered significant when p was less than 0.05.
To compare survival times for the control and 
LND in mice groups, we used the non-parametric Mann-
Whitney test and the log-rank test.
The bioluminescence data were transformed 
using the log(1 + x) function (where x = AvR), in order 
to obtain a more regular and positive distribution. 
Subsequently, these data were normalized by subtracting 
the first observation (day 14) from each of the following 
observations. The Student’s t test was used to compare the 
treatment groups. Survival curves for each treatment were 
estimated via the Kaplan-Meier method, and the log-rank 
test was used to assess the significance of differences in 
both, patients and mice follow-up.
P-values lower than 0.05 were considered significant.
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